The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Chinoform     5-chloro-7-iodo-quinolin-8-ol

Synonyms: Vioform, clioquinol, Enteroquinol, Enteroseptol, Entero-Septol, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Iodochloroxyquinoline

 

Psychiatry related information on Iodochloroxyquinoline

 

High impact information on Iodochloroxyquinoline

  • Compounds that interdict metal-ion binding to Abeta dissolve brain deposits in vitro and one such compound, clioquinol, inhibits Abeta deposition in the Tg2576 mouse model for AD and could be useful clinically [12].
  • Clioquinol is a drug that acts on amyloid by perturbing amyloid's metallo-chemistry, and Clioquinol treatment has been shown to be beneficial in a mouse model of AD [7].
  • We observed a similar increase in the brains of Tg2576 transgenic mice compared with nontransgenic littermates; the increase was inhibited by in vivo treatment with clioquinol, which suggests that brain Abeta accumulation elevates 4-cholesten-3-one levels in AD [1].
  • Here, we explore the effects of iron chelation via either transgenic expression of the iron binding protein ferritin or oral administration of the bioavailable metal chelator clioquinol (CQ) on susceptibility to the Parkinson's-inducing agent 1-methyl-4-phenyl-1,2,3,6-tetrapyridine (MPTP) [13].
  • In this issue of Neuron, Kaur et al. demonstrate that iron chelation by ferritin transgene or the metal chelator clioquinol prevent oxidative damage and MPTP toxicity in mice [2].
 

Chemical compound and disease context of Iodochloroxyquinoline

 

Biological context of Iodochloroxyquinoline

 

Anatomical context of Iodochloroxyquinoline

 

Associations of Iodochloroxyquinoline with other chemical compounds

 

Gene context of Iodochloroxyquinoline

 

Analytical, diagnostic and therapeutic context of Iodochloroxyquinoline

References

  1. Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. Puglielli, L., Friedlich, A.L., Setchell, K.D., Nagano, S., Opazo, C., Cherny, R.A., Barnham, K.J., Wade, J.D., Melov, S., Kovacs, D.M., Bush, A.I. J. Clin. Invest. (2005) [Pubmed]
  2. Ironic fate: can a banned drug control metal heavies in neurodegenerative diseases? Cole, G.M. Neuron (2003) [Pubmed]
  3. clioquinol causes ataxia in rats. Tamura, Z., Kotaki, H., Nakajima, K., Tanimura, Y., Saitoh, Y., Nakagawa, F. Lancet (1982) [Pubmed]
  4. Percutaneous absorption of iodochlorhydroxyquin in humans. Stohs, S.J., Ezzedeen, F.W., Anderson, A.K., Baldwin, J.N., Makoid, M.C. J. Invest. Dermatol. (1984) [Pubmed]
  5. Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan. Baumgartner, G., Gawel, M.J., Kaeser, H.E., Pallis, C.A., Rose, F.C., Schaumburg, H.H., Thomas, P.K., Wadia, N.H. J. Neurol. Neurosurg. Psychiatr. (1979) [Pubmed]
  6. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Chen, D., Cui, Q.C., Yang, H., Barrea, R.A., Sarkar, F.H., Sheng, S., Yan, B., Reddy, G.P., Dou, Q.P. Cancer Res. (2007) [Pubmed]
  7. '...and C is for Clioquinol' - the AbetaCs of Alzheimer's disease. Melov, S. Trends Neurosci. (2002) [Pubmed]
  8. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Nguyen, T., Hamby, A., Massa, S.M. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  9. Transient global amnesia after clioquinol: five personal observations from outside Japan. Mumenthaler, M., Kaeser, H.E., Meyer, A., Hess, T. J. Neurol. Neurosurg. Psychiatr. (1979) [Pubmed]
  10. Transient global amnesia due to clioquinol. Kaeser, H.E. Acta Neurol. Scand., Suppl. (1984) [Pubmed]
  11. Clioquinol for the treatment of Alzheimer's Disease. Jenagaratnam, L., McShane, R. Cochrane database of systematic reviews (Online) (2006) [Pubmed]
  12. The metallobiology of Alzheimer's disease. Bush, A.I. Trends Neurosci. (2003) [Pubmed]
  13. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J.Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M.F., DiMonte, D., Volitaskis, I., Ellerby, L., Cherny, R.A., Bush, A.I., Andersen, J.K. Neuron (2003) [Pubmed]
  14. Oral administration of metal chelator ameliorates motor dysfunction after a small hemorrhage near the internal capsule in rat. Masuda, T., Hida, H., Kanda, Y., Aihara, N., Ohta, K., Yamada, K., Nishino, H. J. Neurosci. Res. (2007) [Pubmed]
  15. Genotoxicity of amebicide and anthelmintic drugs in Escherichia coli pol A+/pol A-. Espinosa-Aguirre, J.J., Aroumir, C., Meza, M.T., Cienfuegos, E., Cortinas de Nava, C. Mutat. Res. (1987) [Pubmed]
  16. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. Gal, S., Fridkin, M., Amit, T., Zheng, H., Youdim, M.B. J. Neural Transm. Suppl. (2006) [Pubmed]
  17. Absorption of 8-hydroxyquinolines through the human skin. Fischer, T., Fagerlund, C., Hartvig, P. Acta Derm. Venereol. (1978) [Pubmed]
  18. Comparison of prophylactic tetracycline and clioquinol in a rabbit model of intestinal infection with Vibrio cholerae and Escherichia coli. Sack, D.A., Cray, W.C., Alam, K. Chemotherapy. (1987) [Pubmed]
  19. Anticancer activity of the antibiotic clioquinol. Ding, W.Q., Liu, B., Vaught, J.L., Yamauchi, H., Lind, S.E. Cancer Res. (2005) [Pubmed]
  20. Clioquinol, a Cu(II)/Zn(II) Chelator, Inhibits Both Ubiquitination and Asparagine Hydroxylation of Hypoxia-inducible Factor-1{alpha}, Leading to Expression of Vascular Endothelial Growth Factor and Erythropoietin in Normoxic Cells. Choi, S.M., Choi, K.O., Park, Y.K., Cho, H., Yang, E.G., Park, H. J. Biol. Chem. (2006) [Pubmed]
  21. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. White, A.R., Du, T., Laughton, K.M., Volitakis, I., Sharples, R.A., Xilinas, M.E., Hoke, D.E., Holsinger, R.M., Evin, G., Cherny, R.A., Hill, A.F., Barnham, K.J., Li, Q.X., Bush, A.I., Masters, C.L. J. Biol. Chem. (2006) [Pubmed]
  22. Hyperbaric oxygen therapy for peripheral nerve damage induced in rabbits with clioquinol. Mukoyama, M., Iida, M., Sobue, I. Exp. Neurol. (1975) [Pubmed]
  23. Clioquinol-zinc chelate: a candidate causative agent of subacute myelo-optic neuropathy. Arbiser, J.L., Kraeft, S.K., van Leeuwen, R., Hurwitz, S.J., Selig, M., Dickersin, G.R., Flint, A., Byers, H.R., Chen, L.B. Mol. Med. (1998) [Pubmed]
  24. Behavioral toxicology, risk assessment, and chlorinated hydrocarbons. Evangelista de Duffard, A.M., Duffard, R. Environ. Health Perspect. (1996) [Pubmed]
  25. Extractive alkylation of biological samples of clioquinol or chloroquinaldol and determination by electron capture gas chromatography. Hartvig, P., Fagerlund, C. J. Chromatogr. (1977) [Pubmed]
  26. Reverse-phase high-performance liquid chromatographic determination of halogenated 8-hydroxyquinoline compounds in pharmaceuticals and bulk drugs. Wojtowicz, E.J. Journal of pharmaceutical sciences. (1984) [Pubmed]
  27. Rapid method for the simultaneous analysis of hydrocortisone and clioquinol in topical preparations by high-performance liquid chromatography. Phoon, K.W., Stubley, C. J. Chromatogr. (1982) [Pubmed]
  28. Increased absorption of iodochlorhydroxyquin by rat intestine in the presence of solubilizing agents. Kasai, M., Kanamitsu, M., Katada, T., Tokumitsu, Y., Itaya, K., Ui, M. Toxicology (1977) [Pubmed]
  29. Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease. Treiber, C., Simons, A., Strauss, M., Hafner, M., Cappai, R., Bayer, T.A., Multhaup, G. J. Biol. Chem. (2004) [Pubmed]
  30. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Cherny, R.A., Atwood, C.S., Xilinas, M.E., Gray, D.N., Jones, W.D., McLean, C.A., Barnham, K.J., Volitakis, I., Fraser, F.W., Kim, Y., Huang, X., Goldstein, L.E., Moir, R.D., Lim, J.T., Beyreuther, K., Zheng, H., Tanzi, R.E., Masters, C.L., Bush, A.I. Neuron (2001) [Pubmed]
  31. Cortin disaster: lissencephaly genes spell double trouble for the developing brain. Clark, G.D., Noebels, J.L. Ann. Neurol. (1999) [Pubmed]
  32. A role for heme in Alzheimer's disease: heme binds amyloid beta and has altered metabolism. Atamna, H., Frey, W.H. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
 
WikiGenes - Universities